MetLife price target raised to $95 from $93 at Mizuho
Mizuho analyst Yaron Kinar raised the firm’s price target on MetLife (MET) to $95 from $93 and keeps an Outperform rating on the shares.
Fiscal Year: January - December
MetLife, Inc. (MET), listed on the NYSE, has a market capitalization of $50.38B. As of May 09, 2026, the stock is trading at $78.08 per share@else an unavailable price , offering investors a clear view of its current market value. MetLife, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 14.91, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. MetLife, Inc. also offers a dividend yield of 2.91%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that MetLife, Inc. (MET) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for MetLife, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for MetLife, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for MetLife, Inc. is 3.84, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, MetLife, Inc. (MET) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether MetLife, Inc. (MET) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of MetLife, Inc. (MET) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of MetLife, Inc.. To access the full SS Score, consider upgrading your subscription.
MetLife, Inc. is a significant player in the industry sector, with a market capitalization of $50.38B and a competitive P/E ratio of 14.91. Investors should compare these metrics with industry peers to gauge whether MetLife, Inc. is outperforming or underperforming within its sector.
Mizuho analyst Yaron Kinar raised the firm’s price target on MetLife (MET) to $95 from $93 and keeps an Outperform rating on the shares.
Barclays analyst Alex Scott raised the firm’s price target on MetLife (MET) to $93 from $89 and keeps an Overweight rating on the shares.
Reports Q1 revenue $19.07B, consensus $19.42B. Comment from Michel Khalaf, President and Chief Executive Officer: “MetLife (MET) delivered exceptional performance in the first quarter, with adjusted e...
NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that John McCallion, executive vice president and chief financial officer, and head of MetLife Investment Management, has provided ...
NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced its first quarter 2026 results. Earnings Return Per Share on Equity (ROE) 1Q 2026 1Q 2026 Net Income $1.74 ROE 18.2% Adjusted...
The dividend will be payable on June 9, 2026, to shareholders of record as of May 12, 2026.
NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that its board of directors has declared a second quarter 2026 common stock dividend of $0.5925 per share, an increase of 4.4% from...
MetLife (MET) has received notice of an unsolicited mini-tender offer by Potemkin to purchase up to 100,000 shares of MetLife common stock from MetLife shareholders. The offer is for approximately
NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has received notice of an unsolicited mini-tender offer by Potemkin Limited (“Potemkin”) to purchase up to 100,000 shares o...
BofA lowered the firm’s price target on MetLife (MET) to $99 from $103 and keeps a Buy rating on the shares. The firm adjusted price target among its U.S. insurance
Mizuho analyst Yaron Kinar lowered the firm’s price target on MetLife (MET) to $93 from $100 and keeps an Outperform rating on the shares. The firm adjusted estimates and targets
Evercore ISI raised the firm’s price target on MetLife (MET) to $96 from $95 and keeps an In Line rating on the shares. The firm adjusted estimates ahead of earnings.
MetLife (MET) Investment Management announced that it originated approximately $26B in private fixed income transactions for clients in 2025, increasing total assets under management on MIM’s private ...
WHIPPANY, N.J.--(BUSINESS WIRE)--MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced that it originated approximately $26 bil...
UBS raised the firm’s price target on MetLife (MET) to $102 from $98 and keeps a Buy rating on the shares. The firm adjusted targets in the North American life
NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the market closes. The earnings news release, financial supp...
Barclays lowered the firm’s price target on MetLife (MET) to $89 from $92 and keeps an Overweight rating on the shares. The firm adjusted targets in the insurance group as
NEW YORK--(BUSINESS WIRE)-- #HR--Small and mid-sized (SMB) businesses are navigating an increasingly complex environment marked by rising costs, heightened employee financial stress, and growing expec...
WHIPPANY, N.J.--(BUSINESS WIRE)-- #MIM--MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced that Andrea Drasites will join th...
Keefe Bruyette re-initiated coverage of MetLife (MET) with an Outperform rating and $87 price target The life insurance sector presents a mixed fundamental picture, and while companies have reduced li...
NEW YORK--(BUSINESS WIRE)-- #MetLife--MetLife, Inc. (NYSE: MET) announced that Jordan Canter will join as head of Federal Government Affairs and Regulatory Policy, effective April 20. She will oversee...
TD Cowen lowered the firm’s price target on MetLife (MET) to $88 from $91 and keeps a Buy rating on the shares. The firm updated its model folowing Q4 results.
MetLife (MET) announced that it has received notice of an unsolicited mini-tender offer by Potemkin to purchase up to 10,000 shares of MetLife common stock from MetLife shareholders. The offer
NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has confirmed its previously announced declaration of the first quarter 2026 dividend of $0.31501229 per share on the compa...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 4.60B | Analyst x1 | |
| 2027 | 4.80B | 4.35% | Analyst x1 |
| 2028 | 3.43B | -28.64% | Est @-28.6% |
| 2029 | 2.77B | -19.20% | Est @-19.2% |
| 2030 | 2.44B | -11.81% | Est @-11.8% |
| 2031 | 2.26B | -7.46% | Est @-7.5% |
| 2032 | 2.16B | -4.43% | Est @-4.4% |
| 2033 | 2.11B | -2.30% | Est @-2.3% |
| 2034 | 2.09B | -0.76% | Est @-0.8% |
| 2035 | 2.10B | 0.21% | Est @0.2% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 14.60B | 1.00 | 14.60B |
| 2025A | 17.09B | 1.00 | 17.09B |
| 2026E | 4.60B | 1.09 | 4.24B |
| 2027E | 4.80B | 1.18 | 4.08B |
| 2028E | 3.43B | 1.28 | 2.68B |
| 2029E | 2.77B | 1.39 | 2.00B |
| 2030E | 2.44B | 1.50 | 1.62B |
| 2031E | 2.26B | 1.63 | 1.38B |
| 2032E | 2.16B | 1.77 | 1.22B |
| 2033E | 2.11B | 1.92 | 1.10B |
| 2034E | 2.09B | 2.08 | 1.00B |
| 2035E | 2.10B | 2.26 | 927.30M |
| Terminal | 35.81B | 2.26 | 15.83B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.